Antimicrobial Therapeutics Market to record USD 42.84 Bn incremental growth; Driven by recent drug approvals and robust pipeline -- Technavio

NEW YORK, Oct. 11, 2022 /PRNewswire/ -- The global antimicrobial therapeutics market size is expected to grow by USD 42.84 billion, accelerating at a CAGR of 5% between 2020 and 2025. Technavio has considered various factors including patient population, incidence rate of diseases, revenue generated by vendors, per capita income, and GDP growth among others to estimate the size of the market. Download PDF Report Sample now to understand the scope of our full report on the global antimicrobial therapeutics market.

The market growth will be driven by recent drug approvals and robust pipeline. The rising prevalence of various diseases has resulted in a high unmet need for the development of drugs with innovative disease modifying agents. This is increasing investments in the R&D of new drugs and vaccines for the treatment of various diseases. For instance, in October 2019, the US FDA approved Xofluza (baloxavir marboxil) developed by F. Hoffmann-La Roche Ltd. The drug is indicated for the treatment of acute, uncomplicated influenza, or flu in individuals aged 12 years and above, who have been symptomatic for no more than 48 hours and who are at a high risk of developing flu-related complications. Similarly, in August 2019, the US FDA granted approval to Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. As a result of these factors, market growth is expected to accelerate during the forecast period.

As per Technavio, the increase in R&D of therapeutic vaccines will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other significant trends and market drivers that will influence market growth over 2021-2025.

The increasing prevalence of various diseases is forcing vendors to develop new vaccines with higher efficacies by increasing their R&D efforts. For instance, Bavarian Nordic AS (Bavarian Nordic) is developing a three-vaccine regimen based on Johnson & Johnson AdVac technology (Ad26.HPV16, Ad26.HPV18) and Bavarian Nordic's MVA-BN technology (MVA.HPV16/18) to treat females with chronic infections with high-risk subtypes of the HPV. Many such developments among vendors are expected to have a positive impact on the growth of the market during the forecast period.

This market research report segments the antimicrobial therapeutics market by application (antiviral, antibacterial, antifungal, and antiparasitic) and geography (North America, Europe, Asia, and ROW).

By application, the market growth in the antiviral segment will be significant during the forecast period. The rising incidence of viral infections such as influenza, hepatitis, COVID-19, and HIV/AIDS is driving the growth of the segment. Also, the presence of a robust pipeline of antibacterial and antiviral drugs is contributing to the growth of the segment.

The North American region led the antimicrobial therapeutics market in 2021, followed by Europe, Asia, and ROW respectively. During the forecast period, North America is expected to register the highest incremental growth due to the increasing incidence of microbial diseases.

Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request Sample Report Here

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

• Sarcoma Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026
• Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 02: Market characteristics
• Exhibit 03: Value Chain Analysis: Pharmaceuticals

• 2.2 Value chain analysis

3 Market Sizing

• 3.1 Market definition 
• Exhibit 04: Offerings of vendors included in the market definition
• Exhibit 05: Market segments

• 3.2 Market segment analysis

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020 - 2025
• Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ billion)
• Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

4 Five Forces Analysis

• 4.1 Five Forces Summary 
• Exhibit 09: Bargaining power of buyers

• 4.2 Bargaining power of buyers 
• Exhibit 10: Bargaining power of suppliers

• 4.3 Bargaining power of suppliers 
• Exhibit 11: Threat of new entrants

• 4.4 Threat of new entrants 
• Exhibit 12: Threat of substitutes

• 4.5 Threat of substitutes

• 4.6 Threat of rivalry 
• Exhibit 13: Threat of rivalry
• Exhibit 14: Market condition - Five forces 2020

• 4.7 Market condition

5 Market Segmentation by Application

• 5.1 Market segments 
• Exhibit 16: Comparison by Application

• 5.2 Comparison by Application 
• Exhibit 17: Antiviral - Market size and forecast 2020-2025 ($ billion)

• 5.3 Antiviral - Market size and forecast 2020-2025
• Exhibit 18: Antiviral - Year-over-year growth 2020-2025 (%)
• Exhibit 19: Antibacterial - Market size and forecast 2020-2025 ($ billion)

• 5.4 Antibacterial - Market size and forecast 2020-2025
• Exhibit 20: Antibacterial - Year-over-year growth 2020-2025 (%)
• Exhibit 21: Antifungal - Market size and forecast 2020-2025 ($ billion)

• 5.5 Antifungal - Market size and forecast 2020-2025
• Exhibit 22: Antifungal - Year-over-year growth 2020-2025 (%)
• Exhibit 23: Antiparasitic - Market size and forecast 2020-2025 ($ billion)

• 5.6 Antiparasitic - Market size and forecast 2020-2025
• Exhibit 24: Antiparasitic - Year-over-year growth 2020-2025 (%)
• Exhibit 25: Market opportunity by Application

• 5.7 Market opportunity by Application

6 Customer landscape

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 28: Geographic comparison

• 7.2 Geographic comparison 
• Exhibit 29: North America - Market size and forecast 2020-2025 ($ billion)

• 7.3 North America - Market size and forecast 2020-2025
• Exhibit 30: North America - Year-over-year growth 2020-2025 (%)
• Exhibit 31: Europe - Market size and forecast 2020-2025 ($ billion)

• 7.4 Europe - Market size and forecast 2020-2025
• Exhibit 32: Europe - Year-over-year growth 2020-2025 (%)
• Exhibit 33: Asia - Market size and forecast 2020-2025 ($ billion)

• 7.5 Asia - Market size and forecast 2020-2025
• Exhibit 34: Asia - Year-over-year growth 2020-2025 (%)
• Exhibit 35: ROW - Market size and forecast 2020-2025 ($ billion

• 7.6 ROW - Market size and forecast 2020-2025
• Exhibit 36: ROW - Year-over-year growth 2020-2025 (%)
• Exhibit 37: Key leading countries

• 7.7 Key leading countries

• 7.8 Market opportunity by geography 
• Exhibit 38: Market opportunity by geography ($ billion)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges 
• Exhibit 40: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Vendor landscape 
• Exhibit 43: Landscape disruption

• 9.2 Landscape disruption 
• Exhibit 44: Industry risks

10 Vendor Analysis

• 10.1 Vendors covered

• 10.2 Market positioning of vendors

• 10.3 AbbVie Inc. 
• Exhibit 49: AbbVie Inc. – Key news
• Exhibit 50: AbbVie Inc. - Key offerings
• Exhibit 51: CSL Ltd. - Overview
• Exhibit 52: CSL Ltd. - Business segments

• 10.4 CSL Ltd. 
• Exhibit 53: CSL Ltd. – Key news
• Exhibit 54: CSL Ltd. - Key offerings
• Exhibit 55: CSL Ltd. - Segment focus
• Exhibit 56: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 57: F. Hoffmann La Roche Ltd. - Business segments

• 10.5 F. Hoffmann La Roche Ltd. 
• Exhibit 58: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 59: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibit 60: Gilead Sciences Inc. - Overview
• Exhibit 61: Gilead Sciences Inc. - Product and service
• Exhibit 62: Gilead Sciences Inc. - Key offerings

• 10.6 Gilead Sciences Inc. 
• Exhibit 63: GlaxoSmithKline Plc - Overview
• Exhibit 64: GlaxoSmithKline Plc - Business segments

• 10.7 GlaxoSmithKline Plc 
• Exhibit 65: GlaxoSmithKline Plc – Key news
• Exhibit 66: GlaxoSmithKline Plc - Key offerings
• Exhibit 67: GlaxoSmithKline Plc - Segment focus
• Exhibit 68: Johnson and Johnson - Overview
• Exhibit 69: Johnson and Johnson - Business segments

• 10.8 Johnson and Johnson 
• Exhibit 70: Johnson and Johnson - Key offerings
• Exhibit 71: Johnson and Johnson - Segment focus
• Exhibit 72: Merck and Co. Inc. - Overview
• Exhibit 73: Merck and Co. Inc. - Business segments

• 10.9 Merck and Co. Inc. 
• Exhibit 74: Merck and Co. Inc. – Key news
• Exhibit 75: Merck and Co. Inc. - Key offerings
• Exhibit 76: Merck and Co. Inc. - Segment focus
• Exhibit 77: Novartis AG - Overview
• Exhibit 78: Novartis AG - Business segments

• 10.10 Novartis AG 
• Exhibit 79: Novartis AG – Key news
• Exhibit 80: Novartis AG - Key offerings
• Exhibit 81: Novartis AG - Segment focus
• Exhibit 82: Pfizer Inc. - Overview
• Exhibit 83: Pfizer Inc. - Business segments
• Exhibit 84: Pfizer Inc. - Key offerings

• 10.11 Pfizer Inc. 
• Exhibit 85: Pfizer Inc. - Segment focus
• Exhibit 86: Sanofi SA - Overview
• Exhibit 87: Sanofi SA - Business segments

• 10.12 Sanofi SA 
• Exhibit 88: Sanofi SA - Key offerings
• Exhibit 89: Sanofi SA - Segment focus

11 Appendix

• 11.1 Scope of the report 
• Exhibit 90: Currency conversion rates for US$

• 11.2 Currency conversion rates for US$ 
• Exhibit 91: Research Methodology

• 11.3 Research methodology 
• Exhibit 92: Validation techniques employed for market sizing
• Exhibit 93: Information sources
• Exhibit 94: List of abbreviations

• 11.4 List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio